Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib biomarker study in ulcerative colitis with peripheral arthritis
2020-003006-31Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in autoimmune colitis and arthritis, sponsored by Policlinico Gemelli. Primary endpoint: Identification of mucosal and synovial biomarkers predicting response to tofacitinib. Started Aug 2021; status: terminated.
02
Drugs
03
Conditions
autoimmune colitisarthritis
Beyond the preview
Go deeper on 2020-003006-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003006-31.